Edoxaban — NZ Medication Guide
📋 Reviewed by a Registered Pharmacist NZ — This information is for general educational purposes only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting, stopping, or changing any medication.
What is Edoxaban?
Edoxaban is a direct oral anticoagulant (DOAC) — a direct factor Xa inhibitor — used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. This medication is funded by Pharmac under Special Authority for AF and VTE.
What is Edoxaban Used For?
Edoxaban is used for stroke and systemic embolism prevention in non-valvular atrial fibrillation, and treatment and prevention of DVT and PE after initial parenteral anticoagulation.
How Does Edoxaban Work?
Edoxaban directly and reversibly inhibits factor Xa, blocking the conversion of prothrombin to thrombin and preventing clot formation. It has a longer half-life than rivaroxaban (10–14 hours) and is administered once daily.
How to Take Edoxaban
Standard adult dose: 60 mg once daily (at the same time each day). Dose reduced to 30 mg once daily in patients with renal impairment (eGFR 15–50 mL/min), low body weight (≤60 kg), or taking certain P-gp inhibitors. For VTE treatment: requires initial 5–10 days of parenteral anticoagulation (heparin) before switching to edoxaban.
Common Side Effects of Edoxaban
- Bleeding (any site)
- Anaemia
- Rash
- Elevated liver enzymes
Serious Side Effects — Seek Medical Attention
Contact your doctor or call 111 immediately if you experience any of the following:
- Major bleeding events
- Spinal/epidural haematoma (with neuraxial anaesthesia)
- Rebound thromboembolism if stopped abruptly without a transition plan
Drug Interactions
Edoxaban may interact with other medicines. Always inform your doctor and pharmacist of all medications you are taking. Key interactions include:
- P-gp inhibitors (amiodarone, verapamil, quinidine — increase edoxaban levels — dose reduction required)
- P-gp inducers (rifampicin, carbamazepine, St John’s Wort — reduce levels — avoid)
- NSAIDs and antiplatelets (increased bleeding risk)
- Antifungals (azole group — increase levels)
New Zealand Prescribing Information
Edoxaban (30 mg, 60 mg tablets — Lixiana®) is funded by Pharmac under Special Authority for non-valvular AF and VTE treatment. It requires an initial period of parenteral anticoagulation before transition for VTE treatment. Renal function monitoring is essential — dose reduction criteria must be assessed at initiation and reviewed regularly.
Frequently Asked Questions
How is edoxaban different from apixaban and rivaroxaban?
All three are direct factor Xa inhibitors. Edoxaban and rivaroxaban are once daily, while apixaban is twice daily. Edoxaban for VTE requires initial heparin treatment before switching. The choice between these agents is guided by indication, renal function, dosing preference, and specific drug interactions.
Should I stop edoxaban before a procedure or surgery?
Yes — edoxaban should generally be stopped 24–48 hours before elective procedures, or longer for high-bleeding-risk surgery or if renal function is impaired. Always consult your cardiologist or haematologist about timing and any bridging therapy needed.
⚠️ Disclaimer: This page is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or a qualified health provider. In New Zealand, medication availability and funding may vary — check with Pharmac or your pharmacist for current information.
Reviewed by a Registered Pharmacist NZ
References & Further Information
The following New Zealand and international resources were used to inform this page: